Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of PF-06865571 alone and with PF-05221304 in adults with biopsy-confirmed NASH and stage 2-3 fibrosis
2019-004775-39Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ervogastat and clesacostat in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (5 arms), sponsored by Pfizer. Started May 2020; status: completed.
02
Drugs
ervogastatclesacostat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2019-004775-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004775-39.